

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

DISCLOSEABLE TRANSACTION

UPDATE ON THE PROPOSED TRANSACTION

References are made to the announcements issued by Sisram Medical Ltd (the “**Company**”) on 16 November, 18 November and 7 December 2018 (the “**Announcements**”) in relation to the proposed acquisition of an aggregate of 60% equity interest in Nova Medical Israel Ltd.. Unless otherwise defined in this announcement, terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company would like to update that, all conditions to the Initial Acquisition have been satisfied and completion of the Initial Acquisition has occurred on 15 January 2019. Upon completion of the Initial Acquisition, Nova Medical Israel Ltd. became a 60%-owned subsidiary of the Company.

On Behalf of the Board
Sisram Medical Ltd
Yi LIU
Chairman

Hong Kong, 15 January 2019

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Jianping HUA as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Yang YANG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.

** for identification purpose only*